Human Breast Cancer Anti Estrogen Resistance 1,BCAR1 ELISA Kit

Contact us for 48 wells and bulk quote

The Human Breast Cancer Anti Estrogen Resistance 1, BCAR1 ELISA Kit is a highly reliable and accurate diagnostic tool designed for the detection and quantification of BCAR1 protein levels in human breast cancer samples. This ELISA kit utilizes a solid-phase sandwich enzyme-linked immunosorbent assay technique, ensuring precise and sensitive measurement of BCAR1 protein concentrations.

Breast cancer is a complex disease, and the development of resistance to anti-estrogen therapies poses a significant challenge in its treatment. BCAR1, also known as p130Cas, has been identified as a key player in the development of anti-estrogen resistance in breast cancer. Therefore, accurate measurement of BCAR1 protein levels can provide valuable insights into the resistance mechanisms and aid in the development of targeted therapies.

The Human Breast Cancer Anti Estrogen Resistance 1, BCAR1 ELISA Kit offers several advantages over traditional detection methods. It provides a simple and user-friendly protocol, allowing for efficient and reproducible results. The kit includes all necessary reagents and controls, ensuring the reliability and consistency of the assay. Additionally, it offers a wide dynamic range and high sensitivity, enabling the detection of low BCAR1 protein levels in clinical samples.

This ELISA kit has been extensively validated using a variety of breast cancer cell lines and patient samples, demonstrating its robustness and accuracy. It is suitable for use in research laboratories, clinical settings, and pharmaceutical companies involved in breast cancer research and drug development.

In summary, the Human Breast Cancer Anti Estrogen Resistance 1, BCAR1 ELISA Kit is a powerful tool for the quantitative measurement of BCAR1 protein levels in human breast cancer samples. Its high sensitivity, accuracy, and ease of use make it an invaluable asset in understanding the mechanisms of anti-estrogen resistance and developing effective therapeutic strategies for breast cancer patients.